Healerz™ For Noses provides relief to the delicate skin under the nose that becomes irritated during cold and allergy season.
Teva Pharmaceuticals USA will delay the sales of generic versions of two Gilead Sciences HIV drugs until June 2013, the company stated.
Drug maker Gilead Sciences has completed its $11.2 billion acquisition of Pharmasset, Gilead said.
Drug maker Gilead Sciences will acquire Pharmasset for $11 billion, or $137 per share, Gilead said Monday.
Gilead Sciences has signed an agreement with Boehringer Ingelheim to gain exclusive worldwide rights to research, develop and commercialize BI's novel anti-retroviral compounds.
Mylan subsidiary Matrix Labs has expanded its licensing agreement with Gilead Sciences.
Ranbaxy will produce and market three HIV/AIDS drugs that currently are in late-stage clinical development by Gilead under a new licensing agreement between the drug makers.
A subsidiary of Johnson & Johnson and Gilead Sciences will collaborate to develop a combination drug for HIV, the two companies said Tuesday.
Drug makers Gilead Sciences and Roche are suing Indian drug maker Natco Pharma concerning a generic version of an influenza treatment, according to published reports.
Drug maker Gilead acknowledged the receipt of an unsolicited mini-tender offer by TRC Capital.
Gilead on Friday announced that the Food and Drug Administration has removed a boxed warning about a possible liver injury risk caused by the drug maker's hypertension treatment.
Gilead Sciences plans to acquire a development-stage pharmaceutical company for up to $120 million, Gilead...